Whey permeate-derived milk acidifier for dairy calves

Received: April 15th, 2022 ; Accepted: May 12th, 2022 ; Published: May 27th, 2022 ; Correspondence: [email protected] milk acidifier obtained from whey permeate fermenting it with dairy propionic acid bacteria was tested in this study to evaluate the effects of milk acidification on the health and growth performance of pre-weaned dairy calves. The study consisted of 30 neonatal Holstein female calves, allocated to three treatments fed unacidified (Control group) or acidified (EG-1 and EG-2 groups) pasteurised milk during the 7–75 day age. Control and EG-1 were fed milk by divided method three times daily till one month of age, then twice daily until weaning; EG-2 was basically fed by the undivided method - one week three times daily (7–14 day age), then once daily. Results demonstrate that animal general health status and faecal scores (FS) were good and the tested acidifier can be used for pre-weaned calf milk acidification. Biochemical and haematological indices of blood at the 30 and 60 day age were within normal reference values with both - divided and undivided - milk feeding methods. Mean live weight (LW; 106.6 ± 9.40 kg on average) and live weight gain (LWG; 911.33 ± 109.04 g day-1 on average) at weaning did not differ between treatments (P > 0.05). Lower intake of starter feed associated with a larger amount of milk consumed was observed in EG-2 animals (P < 0.05). As the results observed regarding growth performance and health indices of all dietary treatment groups of calves were similar, we could anticipate that the acidification benefits would be greater when providing unpasteurised milk, or during the hottest weather when the risks of milk spoilage are greater

Crack determination from boundary measurements—Reconstruction using experimental data

In this work we assess the effectiveness of Electrical Impedance Tomography for determining the presence and the location of an interior crack from boundary measurements. Electrical Impedance Tomography uses boundary voltages and currents to image the interior of a region. We collect the data needed for this nondestructive evaluation technique by laboratory experiments and apply two numerical inversion algorithms to the data. Our experiments show that the data collected are sufficient to give good estimates of crack locations and crack sizes.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/45002/1/10921_2004_Article_BF00567084.pd

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient population

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

PURPOSE: This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4). PATIENTS AND METHODS: Patients were randomly assigned 2:1 to receive 6-week cycles of enzastaurin 500 mg/d (1,125-mg loading dose, day 1) or lomustine (100 to 130 mg/m(2), day 1). Assuming a 45% improvement in progression-free survival (PFS), 397 patients were required to provide 80% power to achieve statistical significance at a one-sided level of .025. RESULTS: Enrollment was terminated at 266 patients (enzastaurin, n = 174; lomustine, n = 92) after a planned interim analysis for futility. Patient characteristics were balanced between arms. Median PFS (1.5 v 1.6 months; hazard ratio [HR] = 1.28; 95% CI, 0.97 to 1.70), overall survival (6.6 v 7.1 months; HR = 1.20; 95% CI, 0.88 to 1.65), and 6-month PFS rate (P = .13) did not differ significantly between enzastaurin and lomustine, respectively. Stable disease occurred in 38.5% and 35.9% of patients and objective response occurred in 2.9% and 4.3% of patients, respectively. Time to deterioration of physical and functional well-being and symptoms did not differ between arms (HR = 1.12; P = .54). Four patients discontinued enzastaurin because of drug-related serious adverse events (AEs). Eleven patients treated with enzastaurin died on study (four because of AEs; one was drug-related). All four deaths that occurred in patients receiving lomustine were disease-related. Grade 3 to 4 hematologic toxicities were significantly higher with lomustine (46 events) than with enzastaurin (one event; P < or = .001). CONCLUSION: Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma

Scattering From Resonant Slots on a Semi-Infinite Cone

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/116072/1/rds19672121437.pd